The verdict
Our read at a glance.
Which benefits are supported within approved product labels and trial-tested populations, and where broad wellness or identity-uncertain product narratives go beyond the evidence.
- The signal
- Large STEP, SUSTAIN, PIONEER, SELECT, FLOW, SOUL, HFpEF, and MASH/NASH evidence streams support specific labeled or trial-tested contexts. Evidence strength is highest when claims stay inside the exact product, population, endpoint, and indication being studied.
- The unknown
- How to interpret long-term population use, discontinuation and maintenance, rare safety signals, access constraints, comparative evidence, confirmatory MASH outcomes, and claims outside studied populations.
- Our read
- Established in specific contexts, with a real safety/product-identity watch. The strongest read is label- and endpoint-specific: do not collapse approved products, compounded products, and broad GLP-1 narratives into one claim.
The mechanism
How it works.
Semaglutide is a long-acting synthetic analog of GLP-1, an incretin hormone the gut releases after eating. It binds and activates the GLP-1 receptor, which acts on appetite centers in the brain to increase satiety, slows gastric emptying, prompts the pancreas to release more insulin only when blood glucose is high, and suppresses glucagon under those same conditions. These are well-established human effects that underpin its approved use in type 2 diabetes and obesity.
Safety & regulatory boundary
The consequential part.
Approved use is not broad wellness proof. Wegovy, Ozempic, and Rybelsus have distinct labels and evidence boundaries, and approved-product evidence should not be transferred to compounded, salt-form, counterfeit, research-use, internet-market, or otherwise identity-uncertain products.
What's next
What we're watching.
Confirmatory MASH outcomes, longer-term safety surveillance, discontinuation data, comparative incretin evidence, kidney and cardiovascular endpoint updates, product-identity enforcement, shortage-policy changes, and how benefit-risk varies by population.
Context
Why this is discussed.
Semaglutide is a reference point for the current obesity-drug era, diabetes care, cardiometabolic risk reduction, and debates about product identity in the GLP-1 market.
The evidence base
66 cited references.
Regulatory & labels28
National Library of Medicine / FDA label · 2026 label listing
National Library of Medicine / FDA label · 2026 label listing
National Library of Medicine / FDA label · 2026 label listing
Food and Drug Administration · 2025/2026
Food and Drug Administration · 2024-03-08
Food and Drug Administration · 2026-03-19
Food and Drug Administration · Current page checked 2026-05-16
Food and Drug Administration · Current page checked 2026-05-16
Food and Drug Administration · 2025-02-21; updated 2026-04-01
Food and Drug Administration · 2025-02-21
Food and Drug Administration · 2026-04-30
Food and Drug Administration · 2025-12-05
Food and Drug Administration · 2026-01-13
European Medicines Agency · 2025
Health Canada · 2026-04-28
Health Canada · 2026-05-01
Therapeutic Goods Administration · Current page checked 2026-05-16
Therapeutic Goods Administration · Current page checked 2026-05-16
World Health Organization · 2024-06-19
American Diabetes Association · 2026
American Diabetes Association · 2026
American Diabetes Association · 2026
American Diabetes Association · 2026
American Gastroenterological Association · 2022
Obesity Canada guideline authors · 2025
National Institute for Health and Care Excellence · 2023
EASL / EASD / EASO · 2024
Peer-reviewed journals10
Garvey et al. · 2022
SELECT investigators · 2024
SELECT investigators · 2024
Aroda et al. · 2017
Rodbard et al. · 2018
SOUL investigators · 2026
Loomba et al. · 2023
Nature Medicine authors · 2025
BMJ / Oxford CEBM authors · 2026
STEP 8 investigators · 2022
Indexed literature (PubMed)28
Wilding et al. · 2021
Davies et al. · 2021
Wadden et al. · 2021
Rubino et al. · 2021
Wilding et al. · 2022
Lincoff et al. · 2023
Perkovic et al. · 2024
Mann et al. · 2026
Marso et al. · 2016
Husain et al. · 2019
McGuire et al. · 2025
Sorli et al. · 2017
Ahmann et al. · 2018
Frias et al. · 2021
Aroda et al. · 2019
Thethi et al. · 2020
Kosiborod et al. · 2023
Butler et al. · 2024
Shah et al. · 2024
Newsome et al. · 2021
Sanyal, Newsome, Kliers et al. · 2025
Mantovani / Sattar et al. · 2025
Systematic review authors · 2023
Meta-analysis authors · 2025
Systematic review authors · 2025
SURPASS-2 investigators · 2021
SURMOUNT-5 investigators · 2025
Keep reading